Pre-transplant thymic function is associated with the risk of cytomegalovirus disease after solid organ transplantation

Clinical Microbiology and Infection

Volumn 21, Issue 5, 2015, Pages 511.e1-511.e7

  Gracia Ahufinger, I ^a,b   Ferrando Martinez S ^c,d,e   Montejo, M ^f   Munoz Villanueva M C ^a,b   Cantisan S ^a,b   Rivero, A ^a,b   Solana, R ^a,b   Leal, M ^c   Torre Cisneros, J ^a,b  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^e BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

^f HOSPITAL DE CRUCES   (Spain)

Author keywords

CMV seronegative; CMV seropositive; Cytomegalovirus replication; Solid organ transplantation; Thymic function

Indexed keywords

THYMOCYTE ANTIBODY;

ADOLESCENT; ADULT; AGED; ARTICLE; CELLULAR IMMUNITY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; FEMALE; GRAFT RECIPIENT; HEART GRAFT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY GRAFT; KIDNEY PANCREAS TRANSPLANTATION; LONGITUDINAL STUDY; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; ORGAN TRANSPLANTATION; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PRIORITY JOURNAL; RISK FACTOR; THYMUS FUNCTION; VIRUS LOAD; CYTOMEGALOVIRUS INFECTIONS; MIDDLE AGED; PHYSIOLOGY; THYMUS; YOUNG ADULT;

CYTOMEGALOVIRUS;

ADOLESCENT; ADULT; AGED; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HUMANS; INCIDENCE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; RISK FACTORS; THYMUS GLAND; YOUNG ADULT;

EID: 84930532373     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2014.12.020     Document Type: Article

References (26)

1. Razonable R.R., Rivero A., Rodriguez A., Wilson J., Daniels J., Jenkins G., et al. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. JInfect Dis 2001, 184:1461-1464.
2. Cope A.V., Sabin C., Burroughs A., Rolles K., Griffiths P.D., Emery V.C. Interrelationships among quantity of human cytomegalovirus (HCMV) DNA in blood, donor-recipient serostatus, and administration of methylprednisolone as risk factors for HCMV disease following liver transplantation. JInfect Dis 1997, 176:1484-1490.
3. Emery V.C., Cope A.V., Sabin C.A., Burroughs A.K., Rolles K., Lazzarotto T., et al. Relationship between IgM antibody to human cytomegalovirus, virus load, donor and recipient serostatus, and administration of methylprednisolone as risk factors for cytomegalovirus disease after liver transplantation. JInfect Dis 2000, 182:1610-1615.
4. Portela D., Patel R., Larson-Keller J.J., Ilstrup D.M., Wiesner R.H., Steers J.L., et al. OKT3 treatment for allograft rejection is a risk factor for cytomegalovirus disease in liver transplantation. JInfect Dis 1995, 171:1014-1018.
5. Torre-Cisneros J. Toward the individualization of cytomegalovirus control after solid-organ transplantation: the importance of the 'individual pathogenic balance'. Clin Infect Dis 2009, 49:1167-1168.
6. de la Torre-Cisneros J., Fariñas M.C., Castón J.J., Aguado J.M., Cantisán S., Carratalá J., et al. GESITRA-SEIMC/REIPI recommendations for the management of cytomegalovirus infection in solid-organ transplant patients. Enferm Infecc Microbiol Clin 2011, 29:735-758.
7. Cantisán S., Lara R., Montejo M., Redel J., Rodríguez-Benot A., Gutiérrez-Aroca J., et al. Pretransplant interferon-γ secretion by CMV-specific CD8+ T cells informs the risk of CMV replication after transplantation. Am J Transplant 2013, 13:738-745.
8. Kotton C.N., Kumar D., Caliendo A.M., Asberg A., Chou S., Danziger-Isakov L., et al. Updated International Consensus Guidelines on the Management of Cytomegalovirus in Solid-Organ Transplantation. Transplantation 2013, 96:333-360.
9. Piliero L.M., Sanford A.N., McDonald-McGinn D.M., Zackai E., Sullivan K.E. T-cell homeostasis in human with thymic hypoplasia due to chromosome 22q 11.2 deletion syndrome. Blood 2004, 103:10205.
10. Mackall C.L., Fleisher T.A., Brown M.R., Andrich M.P., Chen C.C., Feuerstein I.M., et al. Age, thymopoiesis and CD4 T-lymphocyte regeneration after intensive chemotherapy. NEngl J Med 1995, 332:143.
11. Franco J.M., Rubio A., Martínez-Moya M., Leal M., Merchante E., Sánchez-Quijano A., et al. Tcell repopulation and thymic volume in HIV-1-infected patients after highly active antiretroviral therapy. Blood 2002, 99:3702.
12. Jamieson B.D., Douek D.C., Killian S., Hultin L.E., Scripture-Adams D.D., Giorgi J.V., et al. Generation of functional thymocytes in the human adult. Immunity 1999, 10:569-575.
13. Ferrando-Martínez S., Franco J.M., Hernandez A., Ordoñez A., Gutierrez E., Abad A., et al. Thymopoiesis in elderly human is associated with systemic inflammatory status. Age 2009, 31:87-97.
14. Gui J., Mustachio L.M., Su D.M., Craig R.W. Thymus size and age-related thymic involution: Early programming, sexual dimorphism, progenitors and stroma. Aging Dis 2012, 3:280-290.
15. Ferrando-Martínez S., Ruiz-Mateos E., Hernández A., Gutiérrez E., Rodríguez-Méndez Mdel M., Ordoñez A., et al. Age-related deregulation of naive T cell homeostasis in elderly humans. Age 2011, 33:197-207.
16. Humar A., Michaels M. AST ID Working Group on Infectious Disease Monitoring. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosupression trials in recipients of organ transplantation. Am J Transplant 2006, 6:262-274.
17. Ferrando-Martínez S., Franco J.M., Ruiz-Mateos E., Hernández A., Ordoñez A., Gutierrez E., et al. Areliable and simplified sj/beta-TREC ratio quantification method for human thymic output measurement. JImmunol Methods 2010, 352:111-117.
18. Ferrando-Martínez S., Romero-Sánchez M.C., Solana R., Delgado J., de la Rosa R., Muñoz-Fernández M.A., et al. Thymic function failure and C-reactive protein levels are independent predictors of all-cause mortality in healthy elderly humans. Age (Dordr) 2013, 35:251-259.
19. Crough T., Khanna R. Immunobiology of human cytomegalovirus: from bench to bedside. Clin Microbiol Rev 2009, 22:76-98.
20. Gandhi M.K., Khanna R. Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect Dis 2004, 4:725-738.
21. Cervera C., Lozano F., Saval N., Gimferrer I., Ibañez A., Suárez B., et al. The influence of innate immunity gene receptors polymorphisms in renal transplant infections. Transplantation 2007, 83:1493-1500.
22. Stern M., Elsasser H., Honger G., Steiger J., Schaub S., Hess C. The number of activating KIR genes inversely correlates with the rate of CMV infection/reactivation in kidney transplant recipients. Am J Transplant 2008, 8:1312-1317.
23. Kuijpers T.W., Baars P.A., Dantin C., van den Burg M., van Lier R.A., Roosnek E. Human NK cells can control CMV infection in the absence of T cells. Blood 2008, 112:914-915.
24. Hadaya K., de Rham C., Bandelier C., Bandelier C., Ferrari-Lacraz S., Jendly S., et al. Natural killer cell receptor repertoire and their ligands, and the risk of CMV infection after kidney transplantation. Am J Transplant 2008, 8:2674-2683.
25. Sarmiento E., Lanio N., Gallego A., Rodriguez-Molina J., Navarro J., Fernandez-Yañez J., et al. Immune monitoring of anti cytomegalovirus antibodies and risk of cytomegalovirus disease in heart transplantation. Int Immunopharmacol 2009, 9:649-652.
26. Goldfarb N.S., Avery R.K., Goormastic M., Mehta A.C., Schilz R., Smedira N., et al. Hypogammaglobulinemia in lung transplant recipients. Transplantation 2001, 71:242-246.